{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007720","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.347370+00:00","generated_at":"2026-06-18T03:11:30.341666+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx CMO Bedrosian transitions to advisor; Crombez named new CMO","bullets":["Camille Bedrosian transitions to Strategic Development Advisor effective May 1, 2023.","Eric Crombez promoted to EVP, Chief Medical Officer, effective May 1, 2023.","Bedrosian’s new base salary set at $500,000; target bonus 35%; equity award of 6,900 RSUs and 9,200 options.","Severance benefits under amended Offer Letter based on current $600,000 salary and 50% target bonus if termination before May 2024.","Transition is planned, not a sudden departure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007720","json":"https://secwatch.observer/filing/0000950170-23-007720.json","markdown":"https://secwatch.observer/filing/0000950170-23-007720.md","text":"https://secwatch.observer/filing/0000950170-23-007720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/rare-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:11:30.341666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06b10f0d3c","claim":"Eric Crombez was appointed as Executive Vice President, Chief Medical Officer at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"Eric Crombez, M.D., the Company’s current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"7c1fd8d3bb","claim":"Camille L. Bedrosian changed role as Strategic Development Advisor at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Camille L. Bedrosian, M.D., the Company’s Executive Vice President and Chief Medical Officer, will be transitioning to a new role as Strategic Development Advisor to the Company, effective May 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioning"},{"label":"Role","value":"Strategic Development Advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}